The FDA has approved a label expansion for Casgevy to include patients aged 2 years and older with sickle cell disease and ...

AbbVie (ABBV) stock is in focus as the European Commission expands the label for the company's blood cancer therapy Tepkinly ...

Nanoparticles are widely used in medicine to deliver drugs, genes or imaging agents to specific parts of the body. Once a ...

Single-cell RNA-seq AI analysis has become the default way to make sense of the millions of expression measurements a single experiment can now generate. Turning raw sequencing counts into ...

Data from EULAR 2026 show that next-generation CAR T- and NK cell platforms induce powerful, drug-free clinical remissions in patients with highly refractory rheumatic diseases.

Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.

Casgevy also now indicated for transfusion-dependent beta thalassemia in children 2 years ...

Tregzi (clinically known as Orca-T) is an allogeneic cellular immunotherapy consisting of purified regulatory and conventional T cells.

FDA’s PDUFA goal date is November 1, 2026If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell ...

Children who survive a stem-cell transplant only to watch their own donor cells attack their organs now have a ...

Vor Biopharma pivots to telitacicept for autoimmune diseases, backed by $491M cash to 2029. Click here to read an analysis of ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY ® (exagamglogene autotemcel) for the treatment ...